 Shares of Minerva Neurosciences NASDAQ: NERV are soaring higher by over 70 following a purchase by Steve Cohens Point72 Asset Management and the companys submission of a new drug application NDA to the U.S. Food and Drug Administration FDA. The NDA pertains to Minervas roluperidone, which seeks to treat symptoms in patients with schizophrenia. 